Last reviewed · How we verify
Imiquimod ointment
Imiquimod ointment, developed by The University of Hong Kong, is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Imiquimod ointment |
|---|---|
| Also known as | Aldara, Aldara cream, Aldara® (imiquimod) cream 5% |
| Sponsor | The University of Hong Kong |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients (PHASE2, PHASE3)
- Topical 5% Imiquimod Cream for Vulvar Paget's Disease (PHASE3)
- ID HBV Vaccination With Imiquimod in OBI (PHASE2, PHASE3)
- HBV Vaccine in Renal Failure Patients (PHASE2, PHASE3)
- Evaluation of Viral Status of Patients With Plantar Warts Included in VRAIE Study, Non-responder to Study Treatment
- Comparison of Five Treatments in Patients With Plantar Warts (PHASE4)
- Intradermal Influenza Vaccine in the Young (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imiquimod ointment CI brief — competitive landscape report
- Imiquimod ointment updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI